Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

Core Insights - Lexaria Bioscience Corp. has received lead clinical site human research ethics committee (HREC) approval for the 5th study arm of its Phase 1b, 12-week chronic study GLP-1-H24-4 in Australia, allowing dosing to commence [1][2] - The study aims to investigate two GLP-1 drugs, semaglutide and tirzepatide, which together represent over 90% of the global GLP-1 market, showcasing a significant achievement for the company [3] - Lexaria's patented DehydraTECH delivery technology is expected to enhance the performance characteristics of these drugs through oral dosing, as opposed to injections [3][4] Study Details - The study consists of five arms: 1. DehydraTECH-CBD capsules 2. DehydraTECH-semaglutide capsules 3. DehydraTECH-semaglutide combined with DehydraTECH-CBD capsules 4. Rybelsus® tablets (positive control) 5. DehydraTECH-tirzepatide capsules (with newly received HREC approval) [5] - Patient recruitment and dosing are progressing, with the milestone of First Patient First Dose achieved in December 2024 [3] Company Overview - Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 48 patents granted and additional patents pending worldwide [4] - DehydraTECH technology has demonstrated the ability to increase bio-absorption and deliver some drugs more effectively across the blood-brain barrier [4]